Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 26, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Report Third Quarter Financial Results and Provide Business Update on Monday, November 9, 2015

SAN RAMON, Calif., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address...
October 22, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present GALE-302 Preliminary Immunological Data Optimizing GALE-301, and the Phase 2 NeuVax(TM) Data Impact on Cancer Survivorship at Two Upcoming Medical Conferences

SAN RAMON, Calif., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
September 30, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Collaborates With the National Cancer Institute on a Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Ductal Carcinoma in Situ Patients

PORTLAND, Ore., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
September 28, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presents Positive GALE-301 Phase 2a Clinical Trial Data at the European Cancer Congress 2015

GALE-301 is well-tolerated and elicits a strong and dose-dependent in vivo immune response; 1000 mcg identified as optimal dose In the 1000 mcg vaccine dose group (VG), the clinical...
September 14, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present GALE-301 Phase 2a Clinical Trial Data at the European Society for Medical Oncology (ESMO) European Cancer Congress 2015

PORTLAND, Ore., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
September 01, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at Two Upcoming Healthcare Investment Conferences

PORTLAND, Ore., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
August 24, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Announces Independent Data Safety Monitoring Committee Recommends Reduction of Cardiac Toxicity Monitoring for NeuVax(TM) PRESENT Trial

PORTLAND, Ore., Aug. 24, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
August 06, 2015 16:10 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Reports Second Quarter 2015 Financial Results

Completed over-enrollment in the NeuVax Phase 3 PRESENT breast cancer immunotherapy clinical trial and presented encouraging data for GALE-301 and GALE-401 programs Achieved net revenue of...
July 29, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Launches Zuplenz(R) (ondansetron) Oral Soluble Film

Zuplenz is indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting...
July 28, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Report Second Quarter Financial Results on Thursday, August 6, 2015

PORTLAND, Ore., July 28, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right